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lozinskAbstract—Uterine fibroids (UFs) are very common benign tumors of the female reproductive tract. According to
recent reports, magnetic resonanceguided high-intensity ultrasound (MR-HIFU) appears to be a well-tolerated
and efficient treatment option for UFs. However, MR-HIFU still presents several limitations. The treatment is
rarely associated with achieving complete non-perfused volume (NPV). Not all patients are qualified for a final
procedure, and selected women obtain very good results in such treatment. The primary objective of this experi-
mental study was to assess the effect of transvaginal misoprostol and intravenous oxytocin preparation on UF vol-
ume change, sonication time and NPV after MR-HIFU procedure in women of reproductive age with
symptomatic UFs. Secondary outcomes included the effect on the peri-procedural effectiveness of misoprostol
and oxytocin. This study enrolled 247 women with symptomatic UFs; based on gynecologic examinations and
magnetic resonance imaging (MRI) scans, 128 women qualified for MR-HIFU without pharmacologic treatment,
57 women qualified for the misoprostol/diclofenac group and 62 women qualified for the oxytocin group. Phar-
macologic pre-treatment improved NPV compared with non-pharmacologic treatment (average NPV: controls
61.9%§ 25.8%; oxytocin 76.8%§ 20.7%; misoprostol/diclofenac 85.2% § 15.1%; average sonication time: con-
trols 120 min § 56.4%; oxytocin 111 min § 45.4%; misoprostol/diclofenac 80 min § 47.7%). Statistical analysis
did not reveal significant intergroup differences in UF volume changes after 6 mo (controls: n = 40, 37.4% §
27.5%; oxytocin n = 25, 45.8% § 31%; misoprostol/diclofenac n = 19, 33.4% § 23.2%). The misoprostol/diclofe-
nac group, which achieved the highest NPV immediately after the MR-HIFU procedure, was characterized by
the lowest UF volume change percentages 6 mo later. The administration of vasoconstrictor drugs (oxytocin and
misoprostol/diclofenac) to support MR-HIFU in UF treatment is a new issue that may improve the total effective-
ness of this method. Randomized controlled trials are necessary to estimate the real effect of vasoconstrictors on
MR-HIFU. (E-mail: tomasz.lozinski@pro-familia.pl) © 2021 The Author(s). Published by Elsevier Inc. on
behalf of World Federation for Ultrasound in Medicine & Biology. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Uterine fibroids (UFs) are benign tumors of the female
reproductive tract that may cause a variety of clinical
symptoms including abnormal uterine bleedingddress correspondence to: Tomasz ºozinski MD, PhD, Depart-
f Obstetrics and Gynecology Pro-Familia Hospital, 35-033
w, ul. Witolda 6 b, Rzeszow, Poland. E-mail: tomasz.
i@pro-familia.pl
1573(Parker 2007; Stewart et al. 2016) and pelvic pain.
They may also be associated with infertility
(Donnez and Dolmans 2016; Al-Hendy et al. 2017;
Vitagliano et al. 2018). Various methods are used in
treating UFs, from observation or pharmacology to radi-
cal surgery (Donnez and Dolmans 2016; Mas et al. 2017;
Wang et al. 2020).
Magnetic resonanceguided focused ultrasound
(MRgFUS) ablation and a newer method, magnetic
1574 Ultrasound in Medicine & Biology Volume 47, Number 6, 2021resonanceguided high-intensity ultrasound (MR-HIFU),
appear to be well-tolerated and, in many cases, efficient
treatment options for UFs. The MR-HIFU procedure is
more precise and involves adequate volumetric heating of
the whole UF volume with real-time feedback
(Ji et al. 2017; Verpalen et al. 2019). Ultrasound energy
produces a thermal effect in the tissue. This technique is
based on temperature-related protein denaturation. The
resultant necrosis in the tissue leads to the slow stimula-
tion of apoptosis, shrinkage of the tumor and relief of
symptoms (Stewart et al. 2003). The effect of this therapy
depends on numerous factors, including internal tumor
structure (Fan et al. 2018). According to
Funaki et al. (2007), three types of UF tumors are
observed in magnetic resonance imaging (MRI). They are
classified depending on water content, fiber composition
and blood supply. UF types I and II are heated effectively
with the use of ultrasound and are characterized by a
favorable response to the ultrasound beam, while type III
does not respond to this treatment method
(Funaki et al. 2007). There are numerous limitations asso-
ciated with the use of this therapy, such as tumor location,
size, distance between the lesion and the skin, type III
according to Funaki classification, and bowel being
located between the uterus and the anterior abdominal
wall (Peng et al. 2015).
Regrettably, in many cases MR-HIFU/MRgFUS
procedures are still associated with a relatively low
effectiveness, sometimes sub-optimal response to treat-
ment, several limitations and, in most cases, the lack of
an ultimate solution to the problem. However, widely
conducted research (ºozinski et al., 2019a;
Verpalen et al. 2019) involved the exploration of sub-
stance options that may enhance the effectiveness of UF
treatment with ultrasound, uterotonics being one. The
underlying hypothesis assumes an increased destruction
of UFs with ultrasound with a simultaneous perfusion
reduction (Iavazzo et al. 2015).
Oxytocin is a peptide hormone and a neuropeptide.
It mediates a variety of physiologic effects in the target
tissue (e.g., causes uterine contractions and vasoconstric-
tion in the uterine wall, plays a key role in the initiation
of labor, regulates lactation and reproductive behavior)
(Bell et al. 2014). Oxytocin receptor activation triggers a
variety of pathways to stimulate contraction, primarily
by elevating intra-cellular calcium. Some of the cardio-
vascular actions of oxytocin that might modulate
MRgFUS/MR-HIFU procedures include blood pressure
lowering, parasympathetic neuromodulation, vasodila-
tion, immunologic or antioxidant activity and metabolic
effects (Japundzic-Zigon et al., 2020).
Misoprostol is an analogue of prostaglandin E1,
which binds to myometrial cells to cause strong myome-
trial contractions, leading to the expulsion of tissue. Italso causes cervical ripening with the softening and dila-
tion of the cervix (Elati and Weeks 2009). The drug is
recommended for the treatment of postpartum hemor-
rhage when oxytocin is ineffective and is known as sec-
ond-line therapy of postpartum bleeding. According to
available data, clinicians recommend the administration
of misoprostol during myomectomy, as it might reduce
bleeding, decrease the volume of transfusions and
shorten surgery duration (Iavazzo et al. 2015). Accord-
ing to Celik et al. (2003), the use misoprostol causes a
decrease in uterine artery blood flow. The authors sug-
gested that it might be evaluated as an occlusion method
and considered a treatment alternative in patients with
UFs (Celik et al. 2003).
According to previous research published by our
team in 2018, oxytocin administration seems to
improve the efficiency of MR-HIFU therapy
(ºozinski et al. 2018). After several years of monitor-
ing and studying increasing numbers of patients, we
hypothesize that an increased blood flow in UF tissue
decreases the efficiency of ultrasound beam treatment.
Uterotonics cause tumor shrinking, which leads to the
externalization of extracellular fluid and, as a result,
more effective heating of the tissue. Decreased blood
flow in the tumor reduces the cooling effect of the
blood. Our results showed that non-perfused volume
(NPV) significantly improved after oxytocin adminis-
tration (ºozinski et al. 2018).
No data are available to describe the use of miso-
prostol in MRgFUS/MR-HIFU. Therefore, we wanted to
study its possible suitability in this matter. The use of
misoprostol during MRgFUS/MR-HIFU therapy is
hypothesized to be a factor that reduces the cooling effect
of the blood owing to vasoconstriction in the uterus.
AIM OF THE STUDY
The primary objective of this experimental study
was to assess the effect of transvaginal misoprostol/
diclofenac and intravenous oxytocin preparation on soni-
cation time and the effect on the peri-procedural effec-
tiveness of misoprostol/diclofenac and oxytocin on the
MR-HIFU procedure, which was quantified by NPV.
The secondary and technical outcome included UF vol-
ume after MR-HIFU procedure in women of reproduc-
tive age with symptomatic UFs.
MATERIALS ANDMETHODS
Design and patients
This was an experimental, single-center, prospec-
tive cohort study performed as part of a larger prospec-
tive study project to assess the use of MR-HIFU in the
treatment of UFs in women of reproductive age. The
study was approved by the Local Bioethics Committee,
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participants.
A part of the project and our experience with the
sole use of oxytocin compared with controls were
described previously (oxytocin and controls). The study
included a cohort in which we implemented no pharma-
cologic preparation of the patients and introduced oxyto-
cin (ºozinski 2018). Considering the results of the
previous study and the potential effectiveness of miso-
prostol/diclofenac, we introduced consecutive women
undergoing MR-HIFU. All UFs were classified accord-
ing to the International Federation of Gynecology and
Obstetrics (FIGO) classification (Munro et al. 2011).
The inclusion and exclusion criteria were the same as
previously reported (ºozinski et al. 2018). We included
women aged 2043 y with symptomatic UFs (abnormal
uterine bleeding, pain), positive MRI qualification
(Funaki type I or II, a suitable beam window) and will-
ingness to preserve fertility. Exclusion criteria were as
follows: pregnancy, standard contraindications for MRI
and no necessity to preserve fertility according to the
requirements of the funding grant.
All women were tested to exclude pregnancy using a
urine test before the procedure until the end of July 2017,
and after that time pregnancy testing was conducted with
additional human chorionic gonadotropin beta blood test
7 d before the procedure (ºozinski et al., 2019b).
Women were enrolled in the Department of
Obstetrics and Gynecology, Pro-Familia Hospital,
Rzeszow, Poland. During the study, surgical options of
UF treatment were also offered, and MR-HIFU was
available as an alternative treatment option according
to the patient’s preference, detailed qualification and
the lack of contraindications for MR-HIFU. The
patients were divided into three groups: (i) the control
group recruited between May 2015 and October 2016
and treated with MR-HIFU with no pharmacologic
preparation before the procedure; (ii) the oxytocin
group, including women recruited between September
2016 and June 2017 (the patients were administered
oxytocin); and (iii) the misoprostol/diclofenac group,
including women recruited between July 2017 and Sep-
tember 2018 (the patients were administered misopros-
tol/diclofenac). An independent Bioethics Committee
statement (2017) excluded a combination of other
drugs. Women who were recruited between September
2016 and September 2018 but did not receive oxytocin
or misoprostol/diclofenac because of specific contrain-
dications or patients’ preferences were included in the
control group. Standard contraindications for oxytocin
(e.g., allergies, high blood pressure, pregnancy) or
misoprostol/diclofenac (e.g., high blood pressure or
digestive tract cancer) were not considered as exclusion
criteria of the study, but the patients did not receivethose agents and were also included in the control
group.Evaluation and qualification
The qualification included medical history collection
and completing a self-composed questionnaire regarding
the clinical symptoms of UFs. The participants received a
gynecologic examination with speculoscopy and ultra-
sound (Samsung WS80A, Samsung Group, Seoul, South
Korea). All patients were qualified personally by the first
author of this manuscript based on the gynecologic exami-
nation and MRI. Subsequently, an MRI of the pelvic area
was performed using the same device (Philips Ingenia
3.0T system, Philips, Amsterdam, the Netherlands) in all
patients. Basing on the structure in T2-weighted MRIs,
UFs were divided according to the Funaki classification
(Funaki et al. 2007). Type I and II UFs were qualified for
MR-HIFU, whereas patients with type III UFs, with big
areas of necrosis and bowel in the acoustic window, were
disqualified.
The remaining 247 women were included in the
final analysis and divided according to the following pat-
tern: 128 women qualified for MR-HIFU without phar-
macologic treatment, 57 women were included in the
misoprostol/diclofenac group, and 62 women were
included in the oxytocin group.
Patients presented with different types of UFs, and
all patients underwent the MR-HIFU of a single UF,
which was suspected to be responsible for the presence
of symptoms (the largest and closest to the uterine cav-
ity). However, some patients still presented with multi-
ple lesions. Most of the treated UFs were located in the
front, side wall and in the fundus of the uterus. UFs
located in the rear wall were mostly disqualified, as this
area is beyond the acoustic window.MR-HIFU procedure
The preparation and admissions of patients were
standardized. Patients were admitted to the hospital at
6:30 AM on the day of the planned treatment. Patients
were asked to adhere to a semi-liquid diet 3 days before
the treatment. Moreover, 150 mL of sodium dihydrogen
phosphatesodium hydrogen phosphate preparation was
administered on the morning of the procedure. Blood
test results, thyroid-stimulating hormone (TSH), creati-
nine clearance and urea tests were checked. Current
blood test results of TSH, creatinine clearance and urea
were mandatory. MR-HIFU was performed using Sonal-
leve MR-HIFU (Philips, Amsterdam, the Netherlands)
with bladder, rectum or bladder and rectum manipula-
tion.
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During the whole procedure, the patients in the oxy-
tocin group were administered 40 IU of intravenous oxy-
tocin diluted in 500 mL of 5% glucose or 0.9% sodium
chloride at the rate of 5 mL/min. We used a higher con-
centration of oxytocin than recommended by the US
Food and Drug Administration for postpartum hemor-
rhage (40 IU/1000 mL) based on our previous experi-
ence and the common use of such an oxytocin
concentration in local protocols for gynecologic pur-
poses in our country. As regards Pro-Familia Hospital
(the center where the study was conducted), 40 IU of
oxytocin is used only in postpartum hemorrhage. The
manufacturer labels the maximum dose as 40 IU in
1000 mL of 0.9% sodium chloride or in 5% glucose solu-
tion. Moreover, there were no international recommen-
dations or recommendations of well-known agencies or
the producer regarding the limitation for the maximal
concentration. Patients included to the misoprostol/
diclofenac group were asked to use 2 pills of Pfizer
Arthrotec (a combination of non-steroidal anti-inflam-
matory drug and a prostaglandin), 200 mcg misoprostol
and 50 mg diclofenac sodium in one pill (the total of 400
mcg of misoprostol and 100 mg of diclofenac in two
pills) into the vagina, posterior vault, about 30 min
before MR-HIFU procedure. The Bioethical Committee
accepted the use of the described doses of both drugs.Evaluation during and immediately after the procedure:
primary outcome measures
The NPV of the tumor, time of sonication and side
effects were evaluated. NPV is the measurement of suc-
cess in HIFU treatment. It refers to the percentage of
necrotic area in a tumor after sonication. A contrast
medium (gadolinium) was additionally administered
after the procedure to calculate the NPV of UFs as a
measurement of technical treatment success.Follow-up and secondary outcome measures
The patients were invited to the hospital for a fol-
low-up visit 6 mo after the procedure. It was a regular
gynecologic appointment with an ultrasound examina-
tion focusing on UF evaluation. Additionally, in patientsTable 1. Lesions that were treated with MR-HIFU: Types of UFs acc
[n]/%), age (n) and
FIGO type 1 2 3 4
Misoprostol/diclofenac (n = 52) 3 (5.77) 2 (3.84) 21 (40.38) 14 (26.92)
Oxytocin (n = 67) 6 (8.96) 3 (4.47) 26 (38.8) 12 (17.9)
Control (n = 128) 8 (6.25) 6 (4.69) 43 (33.59) 30 (23.43)
P value ns ns ns ns
BMI = body mass index; FIGO = International Federation of Gynaecology a
ultrasound; UF = uterine fibroid.whose NPV exceeded 70% immediately after the proce-
dure, MRI scan was performed to check the exact change
in UF volume. Ultrasound examinations and MRI were
assessed by the same observers who performed pre-oper-
ative diagnostics and the MR-HIFU procedure. We per-
formed a follow up MRI check only in women with the
success of >70% for economic reasons. All the patients
underwent an ultrasound examination, and the results
were compared with the pre-treatment examinations.
Statistical analysis
Values were expressed as means, medians and stan-
dard deviations (SD). Data were analyzed with the Man-
nWhitney test and the analysis of variance. Statistical
significance was set at p < 0.05. All analyses were per-
formed using Statistica software (version 12.0 PL; Stat-
Soft Inc., Tulsa, OK, USA; StatSoft, Krakow, Poland).
RESULTS
Patients
A total of 248 women with symptomatic UFs were
primarily enrolled in this experimental study. However,
one woman underwent MR-HIFU during early preg-
nancy because the procedure was performed in the late
proliferative phase (ºozinski et al. 2019). Therefore, she
was excluded from the study. The median age was 36
years (lower-upper quartile: 3340 y; min-max: 2443
y). The median body mass index (BMI) was 22 kg/m2
(lower-upper quartile: 20.525.5 kg/m2, min-max:
15.738.3 kg/m2). The pre-operative medians of UF
volume assessed with ultrasound and MRI were:
93.40 mL and 95.00 mL (ultrasound p = 0.669; MRI
p = 0.457), respectively (Table 1).
Table 1 includes data concerning the location of
UFs, which were subjected to treatment in the enrolled
patients according to the FIGO by Munro et al. (2011).
No statistical differences occurred between the
groups regarding the proportion of specific types accord-
ing to the FIGO classification (p = 0.957).
The volume of UFs was comparable in all groups
(p = 0.499), so the correlation between the time of soni-
cation and the volume was the same for all patients. The
baseline UF volume seemed larger for the misoprostol/ording to FIGO and Funaki classificaton in each group (number
BMI (kg/m2)
5 6 Age BMI Funaki type I Funaki type II
8 (15.38) 4 (7.69) 35.8 22.87 38 19
12 (17.9) 8 (11.94) 35.4 23.48 45 17
23 (17.96) 18 (14.06) 36.9 23.26 93 35
ns ns ns ns ns
nd Obstetrics; MR-HIFU =magnetic resonanceguided high-intensity
Fig. 1. Average fibroid volume in different groups measured with US and MRI. MRI = magnetic resonance imaging;
US = ultrasound.
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cant with standard deviations. The data are presented in
Figure 1 and Table 2.NPV and sonication time
NPV measured after the procedure is the most
objective parameter to determine MR-HIFU treatment
efficacy. The reduction of UF-related symptoms is the
second of those parameters. In our research, we found a
relationship between the change of UF volume after
treatment and NPV and a reduction in symptoms (self-
completed questionnaires). Despite the lack of direct
dependence, probably owing to the small size of research
groups, we believe that the improvement of NPV or
changes in the volume of UFs might be important for theTable 2. Comparison of average fibroid volume in different












Control 99.04 112.12 p = 0.669
MRI = magnetic resonance imaging; SD = standard deviation.final treatment result (Fig. 2). The use of misoprostol
with diclofenac and oxytocin increased the efficiency of
MR-HIFU therapy in UFs. Pharmacologic pre-treatment
improved NPV compared with non-pharmacologic treat-
ment (61.9% § 25.8%). The highest NPV immediately
after the procedure was obtained with the use of miso-
prostol with diclofenac (85.2% § 15.1%). Oxytocin was
found slightly less effective (76.8%§ 20.7%) than miso-
prostol with diclofenac in achieving higher NPV after
MR-HIFU. The next step of study analysis involved the
intergroup comparison of NPV percentages achieved
immediately after MR-HIFU. Statistical analysis
revealed significant differences between all groups, and
the highest level of significance was found between the
controls and misoprostol/diclofenac-treated group
(p = 0.0000001). The results are presented in Table 3 and
Figure 3.
After NPV analysis, we compared sonication times
between the groups. In this case, the results were also
rather surprising. In patients who received misoprostol
with diclofenac, the average sonication time (80 min)
was almost 40 min shorter compared with patients from
the control group (120 min), whereas in patients who
received oxytocin, the difference was only about 9 min
(111 min). We compared sonication times between all
groups. Statistical analysis showed the highest level of
significance between the controls and misoprostol/diclo-
fenac-treated group (p = 0.000008). No significant differ-
ence was found between oxytocin and the control group
(p = 0.28). The results are presented in Table 4 and
Figure 4.
Fig. 2. Comparison between reduction of symptoms and non-perfused volume and volume change (MRI).
MRI = magnetic resonance imaging.
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As stated before, we assumed that the treatment
success would be the NPV of 70% or greater. Therefore,all patients with the NPV of 70% and higher had an addi-
tional MRI scan during the follow-up visit 6 mo after the
initiation of the protocol. We compared the long-term
Table 3. The number of patients and NPV immediately after MR-HIFU in selected groups.
n NPV SD Misoprostol/diclofenac oxytocin
Misoprostol/diclofenac 52 85.2% +/- 15.1% p=0,045
Oxytocin 67 76.8% +/- 20.7% p=0,045
Controls 128 61.9% +/- 25.8% p=0,0000001 p=0,000017
Summary 247 70.8% +/- 24.5%
non-perfused volume – NPV; number – n; standard deviation – SD
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additional pharmacologic methods (oxytocin or miso-
prostol with diclofenac) in all of those patients. Addi-
tional MRI scans were performed in 84 patients (34% of
the initial group) because of NPV criteria and because
some patients were lost to follow-up. Obviously, it
would be more beneficial if every patient had a control
MRI. However, the lack of financing was the major issue
in this context. Therefore, the results concerning tumor
volume and its change after the treatment are very inter-
esting. However, because of the small size of the groups,
we may treat them as purely technical and secondary. It
is necessary to perform at least a control ultrasound
examination in all patients, which would lower the costs
compared with control MRI scans.
The results for controls, oxytocin and misoprostol/
diclofenac groups were 37.4%, 45.8% and 33.4%,
respectively. The complete data obtained from additional
MRI scans are presented in Table 5 and Figure 5. The
results were consistent with the ultrasound volume testsFig. 3. NPV immediately after MR-HIFU in selected groups (S
sity ultrasound; NPV = non-perfused vperformed in all patients after 6 mo regardless of the
NPV result.
Further steps of statistical analysis involved the
comparison of UF volume reduction achieved 6 mo after
the initial MR-HIFU treatment. Statistical analysis did
not show significant differences between all groups
(p = 0.3).
Additionally, the study involved the analysis of cor-
relation between the age and UF volume with NPV and
sonication time. The results are presented in Table 6.
No significant correlations were found apart from
the one referring to the sonication time and UF volume.
The strongest correlation was observed in case of miso-
prostol and diclofenac use (r = 0.709) (Table 4). The
researchers also analyzed the type of UF according to
the criteria by Funaki et al. (2007) and the differences in
NPV and sonication time depending on UF type I or II
and a drug that was administered. The analysis found
that the shortest sonication time was achieved with the
use of misoprostol with diclofenac as a supporting drugD). MR-HIFU =magnetic resonanceguided high-inten-
olume; SD = standard deviation.
Table 4. The number of patients and MR-HIFU sonication time in selected groups.
n* Sonication time [min] SD Misoprostol/diclofenac Oxytocin
Misoprostol/diclofenac 50 80 +/- 47.7% p=0,00153
Oxytocin 67 111 +/- 45.4% p=0,00153
Controls 122 120 +/- 56.4% p=0,000008 p=0,28
Summary 239 109 +/- 53.8%
minute – min; number – n; standard deviation – SD
(* lack of data about sonication time in 8 patients from the whole group)
1580 Ultrasound in Medicine & Biology Volume 47, Number 6, 2021(p = 0.0000001). The highest NPV percentage was also
noted in the misoprostol/diclofenac group, particularly
in case of type I UFs (p = 0.0000001). We present these
data in Figure 6.DISCUSSION
The study found that misoprostol with diclofenac
had no effect on our most important primary outcome,
UF volume after MR-HIFU, whereas oxytocin adminis-
tration resulted in decreasing UF volume at 6-mo fol-
low-up. Moreover, NPV was higher and sonication times
were lower in the misoprostol/diclofenac and oxytocin
group compared with women who underwent a MR-
HIFU procedure without the use of those drugs. Indeed,
the lack of differences may be treated as very disappoint-
ing, but the time of procedure was significantly reduced,
and it should be regarded as an important findingFig. 4. MR-HIFU sonication times in selected groups (SD).
ultrasound; SD = stanconsidering all benefits associated with shortened proce-
dure time (cost effectiveness). The results indicated that
the application of misoprostol/diclofenac and oxytocin
might increase MR-HIFU effect on UF tissue thermal
destruction. Therefore, it may be concluded that proce-
dures that use MR-HIFU may be modulated with appro-
priate uterotonics. The highest percentages of UF
volume changes were found in the oxytocin group, sug-
gesting that the best results might be obtained with the
use of oxytocin injections during the MR-HIFU proce-
dure. Interestingly, the misoprostol/diclofenac group that
achieved the highest NPV immediately after the MR-
HIFU procedure was characterized by the lowest UF vol-
ume change percentages 6 mo later (Fig. 4).
Considering available literature, numerous authors
expressed the view that MRgFUS/MR-HIFU has the all
potential to become a method of treatment that could
shift traditional patterns of UF therapyMR-HIFU =magnetic resonanceguided high-intensity
dard deviation.
Table 5. Uterine fibroid volume change 6 months after MR-
HIFU: Different groups
UFs after 6 months n Average volume change SD
Misoprostol/diclofenac 19 33.4% §23.2%
Controls 40 37.4% §27.5%
Oxytocin 25 45.8% §31%
Summary 84 39% §27.8%
MR-HIFU =magnetic resonanceguided high-intensity ultrasound;
SD, standard deviation; UF, uterine fibroid.





Misoprostol/diclofenac r = 0.046 r = 0.108
Oxytocin r = 0.038 r = 0.187
Control r = 0.14 r = 0.155





Misoprostol/diclofenac r = 0.709 r = (0.208)
Oxytocin r = 0.524 r = (0.098)
Control r = 0.618 r = (0.105)
All r = 0.569 r = (0.0819)
NPV = non-perfused volume.
The closer to 1, the stronger the correlation; if negative  it is
inversely proportional.
0.0  |r|  0.2 no correlation; 0.2< |r|  0.4  a weak correlation;
0.4 < |r|  0.7  a medium correlation; 0.7 < |r|  0.9  a strong cor-
relation; 0.9 < |r|  1.0  a very strong correlation.
Oxytocin and misoprostol and MR-HIFU in UFs  T. ºOZINSKI et al. 1581(Schlesinger et al. 2013; Ciebiera and ºozinski 2020).
The main aim of available studies is to achieve the best
clinical efficacy, quickest recovery and the lowest mor-
bidity with the use of this method
(Bohlmann et al. 2014; ºozinski et al. 2017). The main
issues related to MRgFUS/MR-HIFU are the optimal
preparation of the device, proper patient qualification
and effective cooperation between the radiologist and
gynecologist (Duc and Keserci 2018). As the efficacy of
this method is still not optimal in some cases, advanced
research is conducted to increase the total effectiveness
of MRgFUS/MR-HIFU therapy with the addition of dif-
ferent drugs (ºozinski et al. 2018). This study has some
limitations, but we are publishing it to highlight that ute-
rotonic administration in MR-HIFU procedures is a cost-
effective and relatively safe modification option of the
procedure and may influence the final results. It is worth
considering how much the cost of the procedure mayFig. 5. Uterine fibroid volume change 6 mo after MR-HIFU p
high-intensity ultrasound; SDchange if the use of certain drugs contributed to the
reduction of procedure duration. Therefore, new research
is necessary to investigate not only other substances, but
also various doses and administration routes of drugs
whose effectiveness were confirmed (e.g., oxytocin).
The best solution would be a double-blind randomized
controlled trial. However, it was impossible for us to
conduct such a study. The presented study is a pioneer-
ing one as no other studies have been performed torocedure (SD). MR-HIFU =magnetic resonanceguided
= standard deviation.
Fig. 6. Sonication time and Funaki type in different groups (p = 0.0000001) and NPV and Funaki type in different
groups (p = 0.0000001). NPV = non-perfused volume.
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Oxytocin and misoprostol and MR-HIFU in UFs  T. ºOZINSKI et al. 1583assess the use of misoprostol/diclofenac as a co-treat-
ment during MR-HIFU. In the previous study conducted
by our team, we proved that the administration of oxyto-
cin is helpful in obtaining higher MR-HIFU treatment
efficacy (ºozinski et al. 2018), which is why we decided
to move further. In this overlapping study, which
included more patients in the control and oxytocin group
and also assessed the use of a different agent, we found
that NPV percentage was the highest and the sonication
time was the shortest in patients who had received miso-
prostol/diclofenac before the procedure. Oxytocin was
slightly less effective in this matter, while the patients
who did not receive any additional treatment had the
lowest NPV and the longest sonication time. The data
are very important from the viewpoint of clinicians who
use MR-HIFU in their practice, as they show completely
different effects of each uterotonic on the course of the
procedure. Interestingly, the results do not translate into
the final effect achieved on UF tumor volume reduction
6 mo after the initial treatment. A group of women who
received misoprostol/diclofenac obtained the poorest
results in total tumor volume reduction. The control
group was rated as average and the oxytocin group was
found to obtain the best results in UF volume reduction.
All these results were consistent with ultrasound imag-
ing, which was performed in all patients regardless of
NPV. However, no significant differences were found
between the groups. Despite this goal of therapy, we
have to remember that UF shrinkage might decrease the
symptoms in some patients as well. Research in major
cohorts of patients might be necessary here. According
to our observations obtained from the present study, we
suspect that misoprostol causes a strong and sudden con-
striction of blood vessels, which stands in line with pre-
vious observations (Yip et al. 2000; Celik et al. 2003).
The highest necrosis (NPV) recorded in misoprostol
group after treatment was probably a false-positive
result. Temporary necrosis was caused by misoprostol
and not the ultrasound beam, and the final effect was
poorer in this group. Numerous patients reported sudden
pain during sonication, probably associated with blood
vessel constriction. In our viewpoint, the dose of miso-
prostol requires further research and a randomized con-
trolled trial. Oxytocin is also a strong vasoconstrictor
(Loichot et al. 2001; Krzymowski and Stefanczyk-Krzy-
mowska 2002). Its contractile effect in case of the uter-
ine muscle and its nourishing vessels appears to be
weaker compared with misoprostol. However, most data
concerning this correlation were retrieved from obstetric
studies (Rajaei et al. 2014; Acharya et al. 2017).
In our opinion, vasoconstriction caused by miso-
prostol at such doses is probably so strong that the
obtained NPV is highly improved over the first stage, but
it makes heating by MR-HIFU ineffective. In case ofintravenous oxytocin, vasoconstriction seems much
more balanced, because not only is NPV higher, but the
final effect of volume change is more beneficial, as we
showed in the previous study as well
(ºozinski et al. 2018). Therefore, it seems to be of key
importance to make a proper choice of a drug and its
dose, which will not only cause the constriction of ves-
sels sufficient to increase necrosis, but also will not
reduce the effectiveness of MR-HIFU. Therefore, the
following question should be answered: Which drug is
more effective in standard regimens? Seemingly, oxyto-
cin will be more beneficial. However, the role of miso-
prostol should not be neglected after this study. We
should perform additional research assessing other
doses, other routes of administration or using both varia-
bles at the same time (e.g., oral or as an insert) as NPV
percentages and sonication times during MR-HIFU were
extraordinary with the use of this compound.
The present study presents new possibilities in MR-
HIFU therapy with the use of, for example, oxytocin as
MR-HIFU support in selected patients. Oxytocin is a
cheap and easily available drug that is well tolerated
with a few contraindications (Page et al. 2017). The
main significance of the presented results is the shorten-
ing of procedures, which reduces the total health care
costs as MRI scans are still expensive. Seemingly, intro-
ducing it as a standard for MR-HIFU therapy might be
really advantageous in case of further positive research
results. In our opinion, better designed studies without a
time-dependent cohort, preferably multi-center random-
ized controlled trials with the blinding of observers and
participants, are necessary to be conclusive for the real
value of additional pharmacologic treatment during MR-
HIFU. Moreover, it seems that based on the results of
this study, it is reasonable to perform a robust investiga-
tion. Certainly, we should also carry out further research
with other drugs or a combination of drugs, such as oxy-
tocin analogues (e.g., carbetocin) or with other prosta-
glandins (e.g., dinoprostone or sulprostone) to find the
most optimal drug that improves the effect of MR-HIFU
therapy. Such an option is interesting for consideration,
and we hope that this study will open new possibilities
for future research.
According to the study protocol, after Local Bioeth-
ics Committee approval and obtaining written informed
consent, we performed MR-HIFU in symptomatic
women, who were also infertile. The safety and effec-
tiveness of MR-HIFU is still poorly assessed in infertile
women (Bohlmann et al. 2014). Considering few preg-
nancies were reported after MR-HIFU, mainly in case
reports and observational studies with a poor design, this
method should be treated as experimental and should not
be offered in regular clinical practice before performing
well-designed randomized controlled trials to compare
1584 Ultrasound in Medicine & Biology Volume 47, Number 6, 2021the effect of the procedure with expectant management,
myomectomy or drugs. It is also worth emphasizing that
there are ongoing studies in China that compare the
effects of MR-HIFU and laparoscopic adenomyosis exci-
sion (Huang et al. 2020). As the results are promising,
we also wait for such studies in UFs.
The main limitation of this study is that it is a non-
randomized controlled trial, and the inclusion of patients
in the misoprostol/diclofenac, oxytocin and control
groups was time-dependent. Hence, unknown confound-
ing factors associated with potential differences in
patient management were probably present. Other limi-
tations are associated with the nature of the interpretation
of NPV with its unknown reliability, which is always
dependent on the observer, although it is still the best
known measurement of MR-HIFU treatment efficacy.
The most objective outcome was the result of the meas-
urements of UF volume in the follow-up. However, the
observers were not blinded, and the best design should
include observers who assess the anatomic results with-
out knowledge about the used drugs. Finally, the
response rate of 34% at the 6-mo follow-up is too low to
make reliable conclusions, and in this study it failed to
show a lasting effect of drug co-treatment, yet further
randomized controlled trials should be performed to test
whether the differences are factual or reflect the prevail-
ing bias and limitations of the study. However, similar
results in ultrasound examinations of the whole group of
patients prompted us to present them. Another issue was
the total dosage of oxytocin and misoprostol or diclofe-
nac. The speed of oxytocin dosage was constant, and the
patients ultimately received different total doses of oxy-
tocin. It means that patients with larger UFs and during
longer procedures received a higher total dose of oxyto-
cin. The total dose of misoprostol that was available in
the bloodstream is also difficult to standardize. Accord-
ing to Zieman et al. (1997), the mean time to peak levels
(34 § 17 min compared with 80 § 27 min, respectively;
p< 0.001) is different between oral and vaginal adminis-
tration. Additionally, diclofenac may also change the
uterine artery pulsatility index, but the data concerning
its influence on UF circulation are unknown (J€arvel€a
et al. 1998).
The strengths are the high standardization of proce-
dures considering measurements, equipment, observers
and follow-up in the study. The present results are prom-
ising for the improvement of peri- and intra-procedural
care with drug preparations. However, the real effect on
the most important results, such as symptoms, is
unknown, and should be assessed in a longer follow-up
period.
The survey of the quality of life (QoL) was not per-
formed in this study, as this endpoint was not planned in
the original design of the study for short follow-up (6mo). We are still collecting data about the QoL in those
patients with the emphasis on long-term changes (up to
24 mo).
In our viewpoint, further research should also cover
an interesting group of patients who decided to undergo
myomectomy after MR-HIFU (with or without drugs).
The analysis of available data will show whether any sig-
nificant differences might predict such patient decisions,
which might allow for the change of their qualification
or not performing MR-HIFU before myomectomy.
CONCLUSIONS
The administration of vasoconstrictor drugs in sup-
port of MR-HIFU in UF treatment is a new issue that may
improve the total effectiveness of this method. MR-HIFU
support with misoprostol at described doses significantly
improved NPV immediately after the procedure and short-
ened the sonication time, but long-term observation
showed that it did not increase the effectiveness of the
therapy. In our opinion, determining the optimal doses of
prostaglandins requires further research. Oxytocin admin-
istration during MR-HIFU improved NPV after the proce-
dure and may also cause better long-term effects related to
UF volume. Based on the observed results it is reasonable
to perform randomized controlled trials to estimate the
real effect of misoprostol and oxytocin on the most impor-
tant outcomes of MR-HIFU for the treatment of UFs.
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